News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Equillium, Inc.
< Previous
1
2
Next >
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
April 01, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
March 25, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
March 22, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
December 21, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
November 13, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
November 08, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
November 06, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Host Analyst & Investor Day
October 03, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the JonesTrading 2023 Healthcare Summit
October 02, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
September 20, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
August 30, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
August 09, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces $7.5 Million Share Repurchase Program
August 02, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
June 01, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
May 15, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
May 11, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
April 24, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates
March 23, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
March 22, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
February 17, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
February 07, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
January 13, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
December 23, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
December 16, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
December 06, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
November 14, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
November 14, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
November 10, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at Two Upcoming Investor Conferences
November 08, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close